The short-term effect of histone deacetylase inhibitors, chidamide and valproic acid, on the NF‑κB pathway in multiple myeloma cells

Liu,Zhaoyun; Jing,Qian; Wang,Yangyang; Li,Yanqi; Mi,Fu; Xiang,Chenhuan; Fu,Rong

doi:10.3892/ijmm.2018.3963

The short-term effect of histone deacetylase inhibitors, chidamide and valproic acid, on the NF‑κB pathway in multiple myeloma cells

Authors:
- Zhaoyun Liu
- Qian Jing
- Yangyang Wang
- Yanqi Li
- Fu Mi
- Chenhuan Xiang
- Rong Fu
View Affiliations

Affiliations: Department of Hematology, Tianjin Medical University General Hospital, Tianjin 300052, P.R. China
Published online on: October 29, 2018 https://doi.org/10.3892/ijmm.2018.3963
Pages: 285-293
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Research regarding histone deacetylase (HDAC) inhibitors (HDACis) has garnered interest for the treatment of multiple myeloma (MM). In addition, the high expression of nuclear factor (NF)‑κB in MM cells is considered an important factor in the occurrence and development of MM. The present study aimed to determine the short‑term effects of HDACis, chidamide and valproic acid (VPA), on MM cells, their effects on NF‑κB and the underlying mechanisms. The present study measured HDAC activity, and the proliferation and apoptosis of U266 and RPMI8226 MM cells following treatment with various concentrations of chidamide and VPA for 6 and 48 h. Western blotting was used to detect the expression levels of phosphorylated (p)‑IκB kinase (IKK)α/β, NF‑κB p65 and inhibitor of NF‑κB (IκBα) in U266 and RPMI8226 cells at various time points following treatment with chidamide and VPA (0, 2, 4 and 6 h). The results revealed that chidamide and VPA had no significant effect on the HDAC activity, proliferation and apoptosis of cells at 6 h; however, cell HDAC activity and proliferation were inhibited, and apoptosis was induced at 48 h. Furthermore, the expression levels of IκBα were gradually increased over time, whereas the expression levels of NF‑κB p65 gradually decreased. These findings indicated that long‑term (48 h) treatment with the HDACis chidamide and VPA inhibited the proliferation and promoted the apoptosis of MM cells; however, these HDACis had little effect on cell proliferation and apoptosis in the short term (6 h). Notably, in the short term (2‑6 h), hyperactivation of NF‑κB was inhibited via the IκBα‑NF‑κB p65 pathway. These findings indicated that cell growth may be inhibited and drug susceptibility may be promoted by blocking the NF‑κB pathway at an early stage, when HDACis are combined with other drugs in the treatment of MM.

View Figures

View References

1	Kohgo Y: Recent advances in multiple myeloma. Int J Clin Oncol. 20:411–412. 2015. View Article : Google Scholar : PubMed/NCBI
2	Palumbo A and Anderson K: Multiple myeloma. Current Opinion in Oncology. 24(Suppl): S12011. View Article : Google Scholar
3	Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
4	Moreau P, Attal M and Facon T: Frontline therapy of multiple myeloma. Blood. 125:3076–3084. 2015. View Article : Google Scholar : PubMed/NCBI
5	Laubach JP, San-Miguel JF, Hungria V, Hou J, Moreau P, Lonial S and Lee JH: An advance in myeloma therapy? Expert Rev Hematol. 10:229–237. 2017. View Article : Google Scholar : PubMed/NCBI
6	Greig SL: Panobinostat: A review in relapsed or refractory multiple myeloma. Targeted Oncol. 11:107–114. 2016. View Article : Google Scholar
7	Ceccacci E and Minucci S: Inhibition of histone deacetylases in cancer therapy: Lessons from leukaemia. Br J Cancer. 114:605–611. 2016. View Article : Google Scholar : PubMed/NCBI
8	Eckschlager T, Plch J, Stiborova M and Hrabeta J: Histone deacetylase inhibitors as anticancer drugs. Int J Mol Sci. 18:14142017. View Article : Google Scholar :
9	Xu L, Tang HL, Gong X, Xin XL, Dong Y, Gao GX, Shu MM and Chen XQ: Inducing effect of chidamide on apoptosis of multiple myeloma cells and its relerance to DNA damage response. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 23:450–454. 2015.In Chinese. PubMed/NCBI
10	Wang DY, Cui YS, Liu YZ, Liu LN, Song YP and Fang BJ: Successful treatment of one case with relapsed refractory multiple myeloma by chidamide in combination with bortezomib and dexamethasone. Zhonghua Xue Ye Xue Za Zhi. 37:4632016.In Chinese.
11	Göttlicher M, Minucci S, Zhu P, Krämer OH, Schimpf A, Giavara S, Sleeman JP, Lo Coco F, Nervi C, Pelicci PG and Heinzel T: Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. Embo J. 20:6969–6978. 2001. View Article : Google Scholar : PubMed/NCBI
12	Kaiser M, Zavrski I, Sterz J, Jakob C, Fleissner C, Kloetzel PM, Sezer O and Heider U: The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myeloma. Haematologica. 91:248–251. 2006.PubMed/NCBI
13	Wang XN and Zhang M: Apoptosis-inducing effect of valproic acid combined with arsenic trioxide on RPMI 8226 cells and its mechanism. Zhongguo Shi Yan Xue Ye Xue Za ZhI. 22:1016–1021. 2014.In Chinese. PubMed/NCBI
14	Dong XF, Song Q, Li LZ, Zhao CL and Wang LQ: Histone deacetylase inhibitor valproic acid inhibits proliferation and induces apoptosis in KM3 cells via downregulating VEGF receptor. Neuro Endocrinol Lett. 28:775–780. 2007.PubMed/NCBI
15	Kitazoe KI, Abe M, Hiasa M, Oda A, Amou H, Harada T, Nakano A, Takeuchi K, Hashimoto T, Ozaki S and Matsumoto T: Valproic acid exerts anti-tumor as well as anti-angiogenic effects on myeloma. Int J Hematol. 89:45–57. 2009. View Article : Google Scholar
16	Qiao L, Yang Y, Zhao RJ, Wang LH, Zhao L, Yan LN, Zhang ZH and Hao CL: Effects of VPA on the expression of notch signaling pathway in multiple myeloma RPMI 8226 cell line. Zhongguo Shi Yan Xue Ye XuezazhI. 24:1449–1453. 2016.In Chinese.
17	Jin YL, Dong BX, Xu L, Tang HL, Gao GX, Gu HT, Shu MM and Chen XQ: Valproic acid represses autophagy and enhances the anti-myeloma activity of DNA-damaging drugs. Zhongguo Shi Yan Xue Ye Xuezazhi. 23:718–721. 2015.In Chinese.
18	Zhang YY, Zhang ZH, Zhao RJ, Li H, Wang TR, Yan LN, Gu CH, Zhao L and Hao CL: Valproic acid activates autophagy in multiple myeloma cell lines RPMI8226 and U266. Zhonghuaxue Ye XuezazhI. 37:478–483. 2016.In Chinese.
19	Fabre C, Grosjean J, Tailler M, Boehrer S, Adès L, Perfettini JL, de Botton S and Fenaux P: NFkappaB inhibition in malignant myeloblasts. Cell Cycle. 7:2139–2145. 2008. View Article : Google Scholar : PubMed/NCBI
20	Dutta J, Fan Y, Gupta N, Fan G and Gélinas C: Current insights into the regulation of programmed cell death by NF-κB. Oncogene. 25:6800–6816. 2006. View Article : Google Scholar : PubMed/NCBI
21	Oeckinghaus A and Ghosh S: The NF-κB family of transcription factors and its regulation. Cold Spring Harb Perspect Biol. a0000342009.
22	Chen ZJ: Ubiquitination in signaling to and activation of IKK. Immunol Rev. 246:95–106. 2012. View Article : Google Scholar : PubMed/NCBI
23	Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F, Lenz G, Hanamura I, Wright G, Xiao W, et al: Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell. 12:115–130. 2007. View Article : Google Scholar : PubMed/NCBI
24	Hayden MS and Ghosh S: NF-κB, the first quarter-century: Remarkable progress and outstanding questions. Genes Dev. 26:203–234. 2012. View Article : Google Scholar : PubMed/NCBI
25	Kannaiyan R, Hay HS, Rajendran P, Li F, Shanmugam MK, Vali S, Abbasi T, Kapoor S, Sharma A, Kumar AP, et al: Celastrol inhibits proliferation and induces chemosensitization through down-regulation of NF-κB and STAT3 regulated gene products in multiple myeloma cells. Br J Pharmacol. 164:1506–1521. 2011. View Article : Google Scholar : PubMed/NCBI
26	Qu X, Du J, Zhang C, Fu W, Xi H, Zou J and Hou J: Arsenic trioxide exerts antimyeloma effects by inhibiting activity in the cytoplasmic substrates of histone deacetylase 6. PLoS One. 7:e322152012. View Article : Google Scholar : PubMed/NCBI
27	Li Z, Yang Z, Peng X, Li Y, Liu Q and Chen J: Nuclear factor-κB is involved in the protocadherin-10-mediated pro-apoptotic effect in multiple myeloma. Mol Med Rep. 10:832–838. 2014. View Article : Google Scholar : PubMed/NCBI
28	Alkalay I, Yaron A, Hatzubai A, Orian A, Ciechanover A and Ben-Neriah Y: Stimulation-dependent IκBα phosphorylation marks the NF-κB inhibitor for degradation via the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA. 92:10599–10603. 1995. View Article : Google Scholar
29	Bharti AC, Shishodia S, Reuben JM, Weber D, Alexanian R, Raj-Vadhan S, Estrov Z, Talpaz M and Aggarwal BB: Nuclear factor-kappaB and STAT3 are constitutively active in CD138⁺ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood. 103:3175–3184. 2004. View Article : Google Scholar : PubMed/NCBI
30	Shi Y, Dong M, Hong X, Zhang W, Feng J, Zhu J, Yu L, Ke X, Huang H, Shen Z, et al: Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. Ann Oncol. 26:1766–1771. 2015. View Article : Google Scholar : PubMed/NCBI
31	Liu L, Chen B, Qin S, Li S, He X, Qiu S, Zhao W and Zhao H: A novel histone deacetylase inhibitor Chidamide induces apoptosis of human colon cancer cells. Biochem Biophys Res Commun. 392:190–195. 2010. View Article : Google Scholar : PubMed/NCBI
32	Ning ZQ, Li ZB, Newman MJ, Shan S, Wang XH, Pan DS, Zhang J, Dong M, Du X and Lu XP: Chidamide (CS055/HBI-8000): A new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell- mediated tumor cell cytotoxicity. Cancer Chemother Pharmacol. 69:901–909. 2012. View Article : Google Scholar
33	Walkinshaw DR and Yang XJ: Histone deacetylase inhibitors as novel anticancer therapeutics. Curr Oncol. 15:237–243. 2008.PubMed/NCBI
34	Liu Z, Ding K, Li L, Liu H, Wang Y, Liu C and Fu R: A novel histone deacetylase inhibitor Chidamide induces G0/G1 arrest and apoptosis in myelodysplastic syndromes. Biomed Pharmacother. 83:1032–1037. 2016. View Article : Google Scholar : PubMed/NCBI
35	Saha SK, Yin Y, Kim K, Yang GM, Dayem AA, Choi HY and Cho SG: Valproic acid induces endocytosis-mediated doxorubicin internalization and shows synergistic cytotoxic effects in hepato-cellular carcinoma cells. Int J Mol Sci. 18:E10482017. View Article : Google Scholar
36	Yang S, Nan P, Li C, Lin F, Li H, Wang T, Zhou C, Zhang X, Meng X, Qian H, et al: Inhibitory effect of chidamide on the growth of human adenoid cystic carcinoma cells. Biomed Pharmacother. 99:608–614. 2018. View Article : Google Scholar : PubMed/NCBI
37	Chen X, Wang H, Zhou M, Li X, Fang Z, Gao H, Li Y and Hu W: Valproic acid attenuates traumatic brain injury-induced inflammation in vivo: Involvement of autophagy and the Nrf2/ARE signaling pathway. Front Mol Neurosci. 11:1–13. 2018. View Article : Google Scholar
38	Qiao Mu H, Wang Z, Kuai Y, Li Q, Wang C, Jiang Y, Wang X, Li X, He WM, et al: Chidamide inhibits aerobic metabolism to induce pancreatic cancer cell growth arrest by promoting Mcl-1 degradation. PLoS One. 11:e01668962016. View Article : Google Scholar : PubMed/NCBI
39	Li Y, Wang Y, Zhou Y, Li J, Chen K, Zhang L, Deng M, Deng S, Li P and Xu B: Cooperative effect of chidamide and chemotherapeutic drugs induce apoptosis by DNA damage accumulation and repair defects in acute myeloid leukemia stem and progenitor cells. Clin Epigenetics. 9:832017. View Article : Google Scholar : PubMed/NCBI
40	GilardiniMontani MS, Granato M, Santoni C, Del Porto P, Merendino N, D’Orazi G, Faggioni A and Cirone M: Histone deacetylase inhibitors VPA and TSA induce apoptosis and autophagy in pancreatic cancer cells. Cell Oncol (Dordr). 40:1–14. 2017.